Active surveillance for localized prostate cancer : a new paradigm for clinical management /

Active surveillance for localized prostate cancer : a new paradigm for clinical management /

Saved in:
Bibliographic Details
Edition:2nd ed.
Imprint:Cham : Springer, ©2018.
Description:1 online resource (249 pages)
Language:English
Series:Current Clinical Urology
Current clinical urology.
Subject:
Prostate -- Cancer -- Diagnosis.
Prostate -- Cancer -- Diagnosis.
Format: E-Resource Book
URL for this record:http://pi.lib.uchicago.edu/1001/cat/bib/11541876
Hidden Bibliographic Details
Other authors / contributors:Klotz, Laurence.
ISBN:9783319627106
3319627104
3319627090
9783319627090
9783319627090
Digital file characteristics:text file
PDF
Notes:Patient Selection for Active Surveillance: Endpoints.
References3: The Role of Fear in Overdiagnosis and Overtreatment; A Tintinnabulation of Fear; The Fears of Patients; The Fears of Doctors; The Fears of the System; The Fears of Society; Flipside Fears; Flipside Fears of Patients; Flipside Fears of Doctors and Other Healthcare Professionals; The Flipside Fear of the System; Flipside Fears of Our Culture and Our Society; What Can Be Done?; References; 4: Ethical and Legal Considerations in Active Surveillance for Prostate Cancer; Introduction; Considerations; Information Provision and Informed Consent.
Print version record.
Summary:This book explores active surveillance in prostate cancer, covering patient selection, risk assessment, 'cancer hysteria' in patients, identifying triggers for intervention, use of PSA kinetics and MRI information and the roles of surveillance and focal therapy.
Other form:Print version: Klotz, Laurence. Active Surveillance for Localized Prostate Cancer : A New Paradigm for Clinical Management. Cham : Springer International Publishing, ©2017 9783319627090
Standard no.:10.1007/978-3-319-62710-6
Table of Contents:
  • Preface to Active Surveillance, Second Edition; Contents; Contributors; 1: Cancer Overdiagnosis and Overtreatment; Background; Cancer Overdiagnosis; Requirements for Overdiagnosis; Prevalence of Microfocal Disease; Disease Detection; Evidence that Early Detection Has Led to Overdiagnosis; References; 2: Can We Screen and Still Reduce Overdiagnosis?; Autopsy Studies of Subclinical Prostate Cancer; Natural History of Untreated Low-ƯRisk Prostate Cancer; Estimation of the Extent of Overdiagnosis; Who to Screen?; Family History of Prostate Cancer; Racial Differences on Prostate Cancer.
  • Genetic Mutations Associating with Higher Risk of Prostate Cancer Is the Presence of a Risk Factor a License to Screen?; When to Screen?; Starting Screening, Baseline PSA at Younger Age; Screening Interval; Ending Age of Screening; How to Screen?; PSA-Based Prostate Cancer Risk Calculators; Novel Biomarkers for Prostate Cancer Prediction; Urine PCA3; Urine TMPRSS2-ERG; Prostate Health Index (PHI); Four-Kallikrein Panel (4 K); STHLM3; Which Novel Biomarker for Prostate Cancer Diagnosis Should We Choose?; Prostate Imaging: Multiparametric MRI of the Prostate; Conclusions.
  • Patient-Physician Communication How Communication Can Influence Decision-Making; Shared Decision-Making; Guidelines; The United States; The Netherlands; Discussion; References; 5: Gleason 6 Tumors Should Still Be Labeled as Cancer; Introduction; Original and Modified Gleason Grading; Improved Prognosis of Current Gleason Score 6; Alternative Non-cancerous Terminology for Gleason 6 Cancer; Clinical Arguments Against Changing Gleason 6 Terminology; Morphological Arguments Against Changing Gleason 6 Terminology; A New Patient-Centric Simplified Prostate Cancer Grading System.
  • Molecular Genetics of Gleason 6 Prostate Cancer Somatic Genetic Alterations; Molecular Subtypes of Prostate Cancer Identified by "Omics"; Other Rearrangements and Copy Number Alterations; Overall Percent of Genome Altered; Somatic Epigenetic Changes; Clonal Relationships Suggest a Common Origin for Gleason Score 7 Tumor Components; RNA Expression Profiles; Other Tissue-Based Molecular Markers; Conclusions/Summary; References; 6: Risk-Based Selection for Active Surveillance; Introduction; Patient Selection for Active Surveillance: Qualitative Considerations.

Similar Items